4th CML-CAB

CML-CAB 2017 III

CMLCAB-Logo

4th CML-CAB: Munich, Germany, 18-19 November 2017

 

On 18-19 November 2017, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, has hosted its fourth meeting to discuss issues of major concern to the CML community.

CML-CAB Members attending the 4th CML-CAB as patient experts:

  • Jan Geissler, Germany (co-chair)
  • Giora Sharf, Israel (co-chair)
  • Jana Pelouchova, Czech Republic
  • Mercedes Arteaga, Argentina (representing Latin America) 
  • Bahija Gouimi, Morocco (representing Africa and the Middle East) 
  • Rita Christensen, Denmark (representing Western Europe)
  • Pat Garcia-Gonzalez - The Max Foundation USA (representing Latin America) 
  • Rod Padua, Philippines (representing East Asia and Pacific)  
  • Felice Bombaci, Italy (Western Europe) 
  • Ferdinand Micho, Kenya (Africa) 
  • Silvia Castillo De Armas, Guatemala (Latin America) 
  • Šarūnas Narbutas, Lithuania (Eastern Europe) 
  • Lisa Machado, Canada (North America) 
  • Cornelia Borowczak, Germany

Plus, the CML Advocates Network team Lidija Pecova and Celia Marín.

 

CML-CAB with Incyte & Takeda, 18th November 2017, 13:00-17:00

The following topics were discussed during the CML-CAB:

  • Clinical Update on Ponatinib
  • Discussion of The Lifecycle Plan for Ponatinib
  • Access Issues
  • Involvement of the CML Community in Research & Development (R&D)
  • Dialogue and Next Steps

Non-confidential minutes of the meeting will be available to CML Advocates Network members soon. 

 

CML-CAB with Novartis, 19th November, 08:00-16:00

The following topics were discussed during the CML-CAB:

  • Clinical Development of ABL001 and Nilotinib 
  • Collaboration Between Novartis and CML Community in CML Drug Development 
  • Therapy-Free Remission 
  • Follow-up Actions and Next Steps

Non-confidential minutes of the meeting will be available to CML Advocates Network members soon. 

 

 

 


 
   
 

EU e-Privacy Directive